LAVA THERAPEUTICS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.73 USD | +3.41% |
|
+0.74% | +72.78% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 124.7 | 85.98 | 37.63 | 67.23 | - | - |
| Enterprise Value (EV) 1 | 8.029 | 85.98 | 37.63 | 67.23 | 67.23 | 67.23 |
| P/E ratio | -2.31 x | -2.88 x | -0.99 x | -1.85 x | -1.35 x | -1.72 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 27.4 x | 4.81 x | 6.04 x | 20.8 x | - | - |
| EV / Revenue | 27.4 x | 4.81 x | 6.04 x | 20.8 x | - | - |
| EV / EBITDA | -3,115,953 x | - | - | - | - | - |
| EV / FCF | -4.66 x | 27.2 x | - | -2.52 x | -2.28 x | -1.82 x |
| FCF Yield | -21.4% | 3.68% | - | -39.7% | -43.8% | -54.8% |
| Price to Book | 1.16 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 25,776 | 26,289 | 26,289 | 26,289 | - | - |
| Reference price 2 | 4.837 | 3.270 | 1.431 | 2.557 | 2.557 | 2.557 |
| Announcement Date | 3/24/22 | 4/11/23 | 3/20/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.186 | 4.545 | 17.88 | 6.233 | 3.231 | - | - |
| EBITDA | - | -40.02 | - | - | - | - | - |
| EBIT 1 | - | -40.32 | -32.12 | -39.83 | -40.2 | -63.37 | -81.8 |
| Operating Margin | - | -887.06% | -179.66% | -638.99% | -1,244.33% | - | - |
| Earnings before Tax (EBT) 1 | - | -41.08 | -29.19 | -38.39 | -39.46 | -63.37 | -81.8 |
| Net income 1 | -13.58 | -41.22 | -29.42 | -38.65 | -38.41 | -57.96 | -72.22 |
| Net margin | -426.37% | -906.94% | -164.55% | -620.09% | -1,188.83% | - | - |
| EPS 2 | - | -2.091 | -1.134 | -1.446 | -1.379 | -1.900 | -1.490 |
| Free Cash Flow 1 | - | -26.73 | 3.166 | - | -26.71 | -29.48 | -36.84 |
| FCF margin | - | -588.22% | 17.71% | - | -826.78% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/2/21 | 3/24/22 | 4/11/23 | 3/20/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.781 | 0.909 | 0.9494 | 0.4677 | 14.67 | 2.434 | 1.136 | 4.72 | 0.0488 | 0.325 | 3.238 | - | - | - |
| EBITDA | - | - | - | -10.77 | -1.351 | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.146 | -8.901 | -10.35 | -10.88 | -1.452 | -10.66 | -12.57 | -12.44 | -9.874 | -5.011 | -7.339 | -11.28 | -12.07 | -12.92 |
| Operating Margin | -401.24% | -979.2% | -1,089.9% | -2,326.92% | -9.89% | -437.88% | -1,106.13% | -263.57% | -20,238.16% | -1,541.65% | -226.68% | - | - | - |
| Earnings before Tax (EBT) 1 | -7.424 | -8.902 | -9.965 | -7.839 | 1.004 | -13.76 | -12.87 | -11.58 | -8.088 | -5.927 | -7.062 | -11.05 | -11.79 | -12.64 |
| Net income 1 | -7.462 | -8.955 | -10.02 | -7.915 | 0.9584 | -13.83 | -12.94 | -11.66 | -8.134 | -5.983 | -7.062 | -11.05 | -11.79 | -12.64 |
| Net margin | -418.98% | -985.1% | -1,055.5% | -1,692.31% | 6.53% | -568.03% | -1,138.89% | -247.13% | -16,670.51% | -1,840.81% | -218.11% | - | - | - |
| EPS 2 | -0.2300 | -0.3454 | -0.3892 | -0.3098 | 0.0384 | -0.5255 | -0.4919 | -0.4409 | -0.3130 | -0.2210 | -0.2030 | -0.3997 | -0.4213 | -0.3937 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/24/22 | 5/17/22 | 9/13/22 | 11/16/22 | 4/11/23 | 6/8/23 | 8/22/23 | 11/16/23 | 3/20/24 | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | 117 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -26.7 | 3.17 | - | -26.7 | -29.5 | -36.8 |
| ROE (net income / shareholders' equity) | - | -72% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | -56.8% | - | - | - | - | - |
| Assets 1 | - | 72.6 | - | - | - | - | - |
| Book Value Per Share | - | 4.170 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 0.69 | - | - | - | - | - |
| Capex / Sales | - | 15.28% | - | - | - | - | - |
| Announcement Date | 3/2/21 | 3/24/22 | 4/11/23 | 3/20/24 | - | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.557
EUR
Average target price
6.684
EUR
Spread / Average Target
+161.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +72.78% | 71.77M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- LVTX Stock
- Financials LAVA Therapeutics N.V.
